Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

Malignant Solid Neoplasm Clinical Trial

Official title:

A Prospective Randomized Controlled Trial of Early Non-Invasive Positive Pressure Ventilation in Patients With Hypoxemic Respiratory Failure and Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02464696
• Other study ID #: 2015-0165
• Secondary ID: NCI-2015-0151420
• Status: Recruiting
• Phase: N/A
• Start date: October 6, 2015
• Est. completion date: October 1, 2024

Study information

• Verified date: March 2024
• Source: M.D. Anderson Cancer Center
• Contact: Nisha Rathi, MD
• Phone: 713-792-5040
• Email: NRathi[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized clinical trial studies how well non-invasive ventilation works in reducing the need for intubation, or placement of a tube in the windpipe, in patients with cancer and respiratory failure. Respiratory failure is a condition in which not enough oxygen passes from the lungs to the blood, and is a common cause of admission to the emergency room in patients with hematological and solid tumor patients. Non-invasive positive pressure ventilation (NIPPV) is a method of delivering oxygen using a mask. It is not yet known whether NIPPV is better at improving the amount of oxygen in the blood, reducing shortness of breath, and the need for intubation than standard high flow oxygen (a tube with 2 prongs placed in the nostrils) in patients with cancer and respiratory failure.

Description:

PRIMARY OBJECTIVES:

I. To determine the percent of patients who meet criteria for intubation within 28 days of study inclusion.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A (NIPPV THERAPY): Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.

ARM B (HIGH FLOW OXYGEN THERAPY): Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.

IDIOPATHIC PULMONARY SYNDROME (IPS) SUBGROUP (INCLUDING DIFFUSE ALVEOLAR HEMORRHAGE):

Patients with IPS receive methylprednisolone daily on days 0-48 and every other day (QOD) on days 49-55 in parallel with NIPPV or oxygen therapy, with a taper at the discretion of the treating physician.

After completion of study, patients are followed up until day 100.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 256
• Est. completion date: October 1, 2024
• Est. primary completion date: October 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Partial pressure of arterial oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio =< 300 mmHg OR a peripheral capillary oxygen saturation (SaO2):FiO2 =< 357

• Have a diagnosed malignancy

• Chest radiograph or computed tomography (CT) scan within =< 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency

• Probability of survival is at least 6 months

Exclusion Criteria:

• Presence of do not resuscitate (DNR)/do not intubate (DNI) orders at study entry

• Clinical evidence of left heart failure as the main etiology for respiratory compromise

• Evidence of active intrathoracic malignancy (primary or metastatic) in the lungs or pleural space that is a significant cause of respiratory insufficiency

• Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure

• Evidence of accessory respiratory muscle use with breathing

• Shock (need for vasopressor therapy or mean arterial pressure [MAP] < 60 despite fluid administration)

• Oliguric acute renal failure (urine output < 500 ml/day) unless already on hemodialysis

• Patient already on NIPPV at the time of screening

• pH < 7.30 or partial pressure of carbon dioxide (pCO2) > 50 (if available)

• Fixed upper airway obstruction

• Airway or facial trauma that would hinder the use of a NIPPV mask

• Uncontrolled tachy or bradyarrhythmia or active myocardial ischemia defined as either:

atrial fibrillation with rapid ventricular response (heart rate [HR] > 120 beats per minute [bpm]), ventricular tachycardia or nonsustained ventricular tachycardia (any rate), supraventricular tachycardia (any rate), third degree heart block (any rate), heart rate less than 40 beats per minute (regardless of the rhythm)

• Active myocardial ischemia defined as a clinical presentation at the time of screening consistent with acute coronary syndrome which includes unstable angina and electrocardiogram (EKG) changes suggestive of an either an acute ST elevation myocardial infarction (new ST elevations or new left bundle branch block) or acute non-ST elevation myocardial infarction (new ST depressions, new T wave inversions)

• Glasgow Coma Scale (GCS) < 8 or inadequate airway protective reflexes

• Undrained pneumothorax/pneumomediastinum

• Copious secretions (> 20 cc's of sputum production per hour or significant hemoptysis defined as > 100 cc's of hemoptysis in a 24 hour period

• Risk for gastric aspiration (ie; ileus, esophageal or bowel obstruction, active vomiting)

• Recent esophageal, gastric or bowel surgery (within 3 weeks of study enrollment)

• Inability to cooperate with NIPPV

• Refusal to receive NIPPV

• Respiratory arrest

Related Conditions & MeSH terms

• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Neoplasms
• Respiratory Insufficiency

Intervention

Drug:
• Methylprednisolone
IPS cohort only

Procedure:
• Oxygen Therapy
Receive high flow oxygen therapy

Device:
• Positive Air Pressure Device
Undergo NIPPV

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent of patients who require intubation or meet criteria for intubation	Fisher's exact test or a chi-squared test will be used to assess the association between two categorical variables. The intubation rate by 28 days and 95% confidence intervals will be estimated for each treatment arm. Logistic regression will be utilized to assess the effect of patient prognostic factors on the intubation rate by 28 days.	Up to 28 days from study inclusion
Secondary	Time to intubation	The Kaplan-Meier method will be used to estimate the time-to-event distribution for each treatment group, and the median time will be provided. The log-rank test will be used to examine the time-to-event distribution of the active treatment group versus that of the control. Time to intubation rate at different time points will be provided by treatment group (i.e. at 7 days, 14 days, 21 days, and 28 days). Since there might be other competing risks for intubation, a competing risk analysis will be performed treating these early events as a competing event for intubation.	Up to 28 days
Secondary	Intensive care unit length of stay	Descriptive statistics, including the mean, standard deviation, median, and range, will be provided. The t-test or Wilcoxon's rank sum test will be used to evaluate the difference between the non-invasive positive pressure ventilation (NIPPV) arm and the control arm.	Up to 28 days
Secondary	Hospital length of stay	Descriptive statistics, including the mean, standard deviation, median, and range, will be provided. The t-test or Wilcoxon's rank sum test will be used to evaluate the difference between the NIPPV arm and the control arm.	Up to 28 days
Secondary	Change in partial pressure of arterial oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio	Descriptive statistics, including the mean, standard deviation, median, and range, will be provided. The t-test or Wilcoxon's rank sum test will be used to evaluate the difference between the NIPPV arm and the control arm.	Baseline up to 28 days

External Links

•   University of Texas MD Anderson Cancer Center Website